{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T23:27:22Z","timestamp":1772666842045,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,4,19]],"date-time":"2014-04-19T00:00:00Z","timestamp":1397865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s40264-014-0160-0","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T22:01:10Z","timestamp":1397858470000},"page":"369-377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adherence to Renal Function Monitoring Guidelines in Patients Starting Antihypertensive Therapy with Diuretics and RAAS Inhibitors: A Retrospective Cohort Study"],"prefix":"10.1007","volume":"37","author":[{"given":"Jan C.","family":"van Blijderveen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine M.","family":"Straus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno H.","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam C.","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia M.","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,19]]},"reference":[{"issue":"2","key":"160_CR1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73\u201387.","journal-title":"Ann Intern Med"},{"key":"160_CR2","first-page":"1865","volume":"64","author":"ML Gelfand","year":"1964","unstructured":"Gelfand ML, Garren MG, Rowan RL. Acute anuria associated with chlorothiazide and hydrochlorothiazide therapy: recovery. N Y State J Med. 1964;64:1865\u201370.","journal-title":"N Y State J Med"},{"issue":"9386","key":"160_CR3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","volume":"362","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759\u201366.","journal-title":"Lancet"},{"issue":"15","key":"160_CR4","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547\u201359.","journal-title":"N Engl J Med"},{"key":"160_CR5","doi-asserted-by":"crossref","first-page":"e8525","DOI":"10.1136\/bmj.e8525","volume":"346","author":"F Lapi","year":"2013","unstructured":"Lapi F, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.","journal-title":"BMJ"},{"key":"160_CR6","unstructured":"The National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care; 2011. http:\/\/www.nice.org.uk\/nicemedia\/live\/12069\/42116\/42116.pdf ."},{"key":"160_CR7","unstructured":"The Dutch College of General Practitioners. Cardiovascular risk management. 1st revision [Cardiovasculair risicomanagement (eerste herziening)]; 2012. https:\/\/www.nhg.org\/standaarden\/volledig\/cardiovasculair-risicomanagement#Begrippen ."},{"issue":"7178","key":"160_CR8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/bmj.318.7178.234","volume":"318","author":"PA Kalra","year":"1999","unstructured":"Kalra PA, et al. Questionnaire study and audit of use of angiotensin converting enzyme inhibitor and monitoring in general practice: the need for guidelines to prevent renal failure. BMJ. 1999;318(7178):234\u20137.","journal-title":"BMJ"},{"issue":"4","key":"160_CR9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1525-1497.2005.40182.x","volume":"20","author":"JS Hurley","year":"2005","unstructured":"Hurley JS, et al. Laboratory safety monitoring of chronic medications in ambulatory care settings. J Gen Intern Med. 2005;20(4):331\u20133.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"160_CR10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pds.1217","volume":"16","author":"MA Raebel","year":"2007","unstructured":"Raebel MA, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf. 2007;16(1):55\u201364.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"160_CR11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00228-007-0431-0","volume":"64","author":"M Gerardin-Marais","year":"2008","unstructured":"Gerardin-Marais M, et al. Diuretic drug therapy monitoring in the elderly: a cohort study. Eur J Clin Pharmacol. 2008;64(4):433\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"160_CR12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2125.2010.03654.x","volume":"70","author":"JJ Coleman","year":"2010","unstructured":"Coleman JJ, et al. Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care. Br J Clin Pharmacol. 2010;70(1):109\u201317.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"160_CR13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/11587250-000000000-00000","volume":"34","author":"JE Bootsma","year":"2011","unstructured":"Bootsma JE, et al. Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors: a retrospective cohort study in the Netherlands. Drug Saf. 2011;34(7):605\u201314.","journal-title":"Drug Saf"},{"issue":"3","key":"160_CR14","doi-asserted-by":"crossref","first-page":"e34187","DOI":"10.1371\/journal.pone.0034187","volume":"7","author":"JP Fournier","year":"2012","unstructured":"Fournier JP, et al. Laboratory monitoring of patients treated with antihypertensive drugs and newly exposed to non steroidal anti-inflammatory drugs: a cohort study. PLoS ONE. 2012;7(3):e34187.","journal-title":"PLoS ONE"},{"issue":"601","key":"160_CR15","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.3399\/bjgp12X653561","volume":"62","author":"AF Geerts","year":"2012","unstructured":"Geerts AF, et al. A pharmacy medication alert system based on renal function in older patients. Br J Gen Pract. 2012;62(601):e525\u20139.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"160_CR16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0036933013482634","volume":"58","author":"L Mathieson","year":"2013","unstructured":"Mathieson L, Severn A, Guthrie B. Monitoring and adverse events in relation to ACE inhibitor\/angiotensin receptor blocker initiation in people with diabetes in general practice: a population database study. Scott Med J. 2013;58(2):69\u201376.","journal-title":"Scott Med J"},{"issue":"5","key":"160_CR17","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/pds.1935","volume":"19","author":"SE McDowell","year":"2010","unstructured":"McDowell SE, et al. Laboratory monitoring and adverse patient outcomes with antihypertensive therapy in primary care. Pharmacoepidemiol Drug Saf. 2010;19(5):482\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4\u20135","key":"160_CR18","first-page":"339","volume":"38","author":"AE Vlug","year":"1999","unstructured":"Vlug AE, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med. 1999;38(4\u20135):339\u201344.","journal-title":"Methods Inf Med"},{"issue":"10","key":"160_CR19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.7326\/0003-4819-119-10-199311150-00011","volume":"119","author":"J Lei van der","year":"1993","unstructured":"van der Lei J, et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med. 1993;119(10):1036\u201341.","journal-title":"Ann Intern Med"},{"issue":"6","key":"160_CR20","first-page":"396","volume":"142","author":"E Hvidberg","year":"1980","unstructured":"Hvidberg E, Andersen AH. New classification of drugs. The Medical list and the Drug catalogue are introduced in Anatomical\u2013Therapeutic\u2013Chemical classification code (ACT-code) in 1981. Ugeskr Laeger. 1980;142(6):396\u20137.","journal-title":"Ugeskr Laeger"},{"issue":"5 Pt 1","key":"160_CR21","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-8703(99)70009-8","volume":"138","author":"EL Knight","year":"1999","unstructured":"Knight EL, et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J. 1999;138(5 Pt 1):849\u201355.","journal-title":"Am Heart J"},{"issue":"9","key":"160_CR22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"160_CR23","unstructured":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):19\u201362."},{"issue":"4","key":"160_CR24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5694\/j.1326-5377.2000.tb125548.x","volume":"172","author":"MC Thomas","year":"2000","unstructured":"Thomas MC. Diuretics, ACE inhibitors and NSAIDs\u2014the triple whammy. Med J Aust. 2000;172(4):184\u20135.","journal-title":"Med J Aust"},{"key":"160_CR25","unstructured":"Verduijn M, Folmer H. Pharmacotherapeutic guideline pain management [Farmacotherapeutische richtlijn pijnbestrijding]; 2007. http:\/\/download.nhg.org\/FTP_NHG\/standaarden\/FTR\/Pijnbestrijding_text.html#noot18 ."},{"issue":"2","key":"160_CR26","first-page":"465 e1\u20132","volume":"31","author":"TF Platts-Mills","year":"2013","unstructured":"Platts-Mills TF, et al. Life-threatening hyperkalemia after 2\u00a0days of ibuprofen. Am J Emerg Med. 2013;31(2):465 e1\u20132.","journal-title":"Am J Emerg Med"},{"issue":"2","key":"160_CR27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.ki.5002297","volume":"72","author":"CY Hsu","year":"2007","unstructured":"Hsu CY, et al. Community-based incidence of acute renal failure. Kidney Int. 2007;72(2):208\u201312.","journal-title":"Kidney Int"},{"issue":"4","key":"160_CR28","doi-asserted-by":"crossref","first-page":"c407","DOI":"10.1159\/000324164","volume":"118","author":"MA Onuigbo","year":"2011","unstructured":"Onuigbo MA. Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients? Nephron Clin Pract. 2011;118(4):c407\u201319.","journal-title":"Nephron Clin Pract"},{"issue":"20","key":"160_CR29","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"LF Fried","year":"2013","unstructured":"Fried LF, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892\u2013903.","journal-title":"N Engl J Med"},{"key":"160_CR30","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","volume":"346","author":"H Makani","year":"2013","unstructured":"Makani H, et al. Efficacy and safety of dual blockade of the renin\u2013angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360.","journal-title":"BMJ"},{"key":"160_CR31","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2165\/11593980-000000000-00000","volume":"34","author":"SE McDowell","year":"2011","unstructured":"McDowell SE, Ferner RE. Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions: a systematic review. Drug Saf. 2011;34:1049\u201359.","journal-title":"Drug Saf"},{"issue":"10","key":"160_CR32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jama.2013.277353","volume":"310","author":"NS Bardach","year":"2013","unstructured":"Bardach NS, et al. Effect of pay-for-performance incentives on quality of care in small practices with electronic health records: a randomized trial. JAMA. 2013;310(10):1051\u20139.","journal-title":"JAMA"},{"key":"160_CR33","first-page":"CD008451","volume":"9","author":"A Scott","year":"2011","unstructured":"Scott A, et al. The effect of financial incentives on the quality of health care provided by primary care physicians. Cochrane Database Syst Rev. 2011;9:CD008451.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"160_CR34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11906-012-0326-z","volume":"15","author":"LC Roksnoer","year":"2013","unstructured":"Roksnoer LC, et al. Urinary markers of intrarenal renin\u2013angiotensin system activity in vivo. Curr Hypertens Rep. 2013;15(2):81\u20138.","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"160_CR35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/1479164112463710","volume":"10","author":"J Wong","year":"2013","unstructured":"Wong J. Is there benefit in dual renin\u2013angiotensin\u2013aldosterone system blockade? No, yes and maybe: a guide for the perplexed. Diab Vasc Dis Res. 2013;10(3):193\u2013201.","journal-title":"Diab Vasc Dis Res"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-014-0160-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0160-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T01:50:46Z","timestamp":1597715446000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-014-0160-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,19]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["160"],"URL":"https:\/\/doi.org\/10.1007\/s40264-014-0160-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,19]]}}}